Engineering Scalable Biologics: Gefjon Pharma’s Modular OMV Platform for High‑Yield, Cost‑Effective Production, Powered by NorthX Biologics’ Extensive GMP Manufacturing Expertise

• Outer membrane vesicles (OMVs) are self-adjuvanting bacterial nanoparticles for next-generation vaccines and bioindustrials. This co-presentation introduces Gefjon Pharma’s hyper-vesiculating OMV platform and proprietary extraction method, enabling high-yield, de-risked and cost-effective production of many classes of protein-based pharmaceuticals
• The value of their platform is illustrated by their first asset, a broad-protective E. coli vaccine
• NorthX Biologics then presents the CDMO route to clinical and commercial supply — fermentation process development, scalable purification, and GMP manufacturing — with a focus on preserving yield, purity, and vesicle integrity during scale-up

Speakers: